Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Language
Publication year range
1.
Cornea ; 43(5): 644-647, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38265274

ABSTRACT

PURPOSE: This study aimed to report a case of persistent keratouveitis associated with mpox virus infection in an immunocompetent patient with a history of laser-assisted in situ keratomileusis (LASIK), leading to the need for flap removal. METHODS: A comprehensive literature review was conducted, and a detailed case report was presented. RESULTS: A 44-year-old immunocompetent male patient with a history of LASIK and HIV infection presented with conjunctival and corneal lesions indicative of mpox infection. Despite initial topical treatment, the condition worsened, leading to severe epithelial and stromal keratitis with anterior chamber inflammation. Polymerase chain reaction testing confirmed the presence of mpox virus in conjunctival, corneal, and aqueous humor samples. The patient underwent various treatments, including tecovirimat, oral and topical corticosteroids, and topical trifluridine, and eventually flap removal with amniotic membrane application. Subsequent polymerase chain reaction testing of the aqueous humor yielded negative results, and the cornea gradually reepithelialized without inflammation. After 8 months, the patient's eye remained stable, with a central stromal scar. CONCLUSIONS: This case highlights the rare occurrence of mpox-associated keratouveitis and emphasizes the challenges faced in its management. The successful outcome achieved through a combination of antiviral therapy, antiinflammatories, and surgical intervention underscores the importance of a multidisciplinary approach in managing such cases.


Subject(s)
HIV Infections , Keratitis , Keratomileusis, Laser In Situ , Mpox (monkeypox) , Uveitis , Male , Humans , Adult , Keratomileusis, Laser In Situ/adverse effects , Cornea , Keratitis/chemically induced , Keratitis/diagnosis , Keratitis/drug therapy , Uveitis/complications , Inflammation
2.
Iberoam. j. med ; 5(1): 46-50, 2023. graf
Article in English | IBECS | ID: ibc-226655

ABSTRACT

Pierre Robin sequence (PRS) is an inherited disorder that affects one in between 8,500 and14,000 people and is characterized by a triad of clinical signs. These include micrognathia,glossoptosis and obstruction of the upper airway, typically associated with palatal cleft.PRS has also been associated with various ocular complications, including high congenitalmyopia, congenital glaucoma, and retinal detachment.Because of the clinical importance of PRS, it is critical to illustrate the features of the Robinsequence to clearly define its primary and secondary clinical signs. We describe a patientwith PRS who developed keratoconus as a rare manifestation of the disease and its management. (AU)


La secuencia de Pierre Robin (PRS) es una patología hereditaria que afecta a una de entre8.500 y 14.000 personas y está caracterizada por una triada de signos. Estos incluyenmicrognatia, glosoptosis y obstrucción de vías aéreas altas, típicamente asociados a labioleporino.PRS ha sido también relacionado con afectación oftalmológica, incluyendo miopía congénita,glaucoma congénito o desprendimiento de retina.Debida a la importancia clínica de la PRS, es fundamental describir las distintascaracterísticas de la secuencia Pierre Robin, para así definir los signos principales ysecundarios de la patología. Describimos el caso de una paciente con PRS que desarrollóqueratocono como una extraña manifestación de la enfermedad. (AU)


Subject(s)
Humans , Female , Young Adult , Pierre Robin Syndrome/classification , Keratoconus , Corneal Topography , Cornea
4.
Vasc Health Risk Manag ; 16: 231-239, 2020.
Article in English | MEDLINE | ID: mdl-32606719

ABSTRACT

Erectile dysfunction (ED) is defined as a man's consistent or recurrent inability to attain and/or maintain penile erection enough for successful vaginal intercourse. ED affects a large part of the population, increasing its incidence with age and comorbidities. It is estimated by the year 2025, 322 million men will suffer from ED. Incidence of ED has been related not only to chronic diseases such as diabetes mellitus, metabolic syndrome, hyperlipidemia, psychiatric diseases or urinary tract diseases, but also to hypertension and especially to antihypertensive treatments. This review summarizes current knowledge about the management of ED in hypertensive men and its role as cardiovascular disease predictor.


Subject(s)
Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Erectile Dysfunction/therapy , Hypertension/drug therapy , Penile Erection/drug effects , Phosphodiesterase 5 Inhibitors/therapeutic use , Antihypertensive Agents/adverse effects , Clinical Decision-Making , Erectile Dysfunction/diagnosis , Erectile Dysfunction/epidemiology , Erectile Dysfunction/physiopathology , Humans , Hypertension/diagnosis , Hypertension/epidemiology , Hypertension/physiopathology , Male , Phosphodiesterase 5 Inhibitors/adverse effects , Risk Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL